ATE454898T1 - Annexin zur prävention von der ruptur des plaques - Google Patents

Annexin zur prävention von der ruptur des plaques

Info

Publication number
ATE454898T1
ATE454898T1 AT05735990T AT05735990T ATE454898T1 AT E454898 T1 ATE454898 T1 AT E454898T1 AT 05735990 T AT05735990 T AT 05735990T AT 05735990 T AT05735990 T AT 05735990T AT E454898 T1 ATE454898 T1 AT E454898T1
Authority
AT
Austria
Prior art keywords
annexin
binding
immunoglobulins
atherosclerosis
atherothrombosis
Prior art date
Application number
AT05735990T
Other languages
English (en)
Inventor
Anna Frostegard
Johan Frostegard
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Application granted granted Critical
Publication of ATE454898T1 publication Critical patent/ATE454898T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Escalators And Moving Walkways (AREA)
  • Cosmetics (AREA)
AT05735990T 2004-04-15 2005-04-15 Annexin zur prävention von der ruptur des plaques ATE454898T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52138504P 2004-04-15 2004-04-15
PCT/GB2005/001451 WO2005099744A1 (en) 2004-04-15 2005-04-15 Annexin v for preventing atherothrombois and plaque rupture

Publications (1)

Publication Number Publication Date
ATE454898T1 true ATE454898T1 (de) 2010-01-15

Family

ID=34966761

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05735990T ATE454898T1 (de) 2004-04-15 2005-04-15 Annexin zur prävention von der ruptur des plaques

Country Status (15)

Country Link
US (1) US20080044404A1 (de)
EP (1) EP1755642B1 (de)
JP (2) JP2007532617A (de)
CN (1) CN1997385B (de)
AT (1) ATE454898T1 (de)
AU (1) AU2005232436C1 (de)
CA (1) CA2563408C (de)
CY (1) CY1109959T1 (de)
DE (1) DE602005018914D1 (de)
DK (1) DK1755642T3 (de)
ES (1) ES2356364T3 (de)
PL (1) PL1755642T3 (de)
PT (1) PT1755642E (de)
SI (1) SI1755642T1 (de)
WO (1) WO2005099744A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
MX2010006719A (es) * 2007-12-18 2010-09-28 Athera Biotechnologies Ab Compuestos y metodos para el tratamiento de enfermedad vascular.
HUE035034T2 (en) 2008-02-22 2018-05-02 Annexin Pharmaceuticals Ab Compounds and methods for preventing or treating restenosis
EP2350112A4 (de) 2008-10-03 2013-01-16 Advanced Proteome Therapeutics Inc Ortsspezifische n-terminus-proteinmodifikationen und konjugatbildung
WO2010043045A1 (en) 2008-10-17 2010-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
EP3805758A1 (de) * 2008-12-19 2021-04-14 Medirista Biotechnologies AB Oxidiertes cardiolipin als neuer proinflammatorischer faktor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
HUE030922T2 (en) 2011-04-05 2017-06-28 Annexin Pharmaceuticals Ab Therapeutic and prophylactic procedures, applications and preparations containing annexin A5
WO2013109144A1 (en) * 2012-01-18 2013-07-25 Stichting Katholieke Universiteit Annexin a5 snp in atherosclerosis
GB2552724B (en) * 2015-09-17 2020-05-06 Annexin Pharmaceuticals Ab Purification of Annexin A5 by anion exchange and affinity chromatography
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB2552853B (en) * 2015-09-17 2018-11-21 Annexin Pharmaceuticals Ab Purification of Annexin A5 from a composition that includes a calcium ion chelator
CN105327042A (zh) * 2015-12-16 2016-02-17 刘爱玲 一种治疗颈动脉斑块的中药药膏及制备方法
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
CN108159421B (zh) * 2018-02-05 2021-05-18 苏州大学 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN117897399A (zh) 2021-06-14 2024-04-16 Inserm(法国国家健康医学研究院) 突变的膜联蛋白a5多肽及其在治疗目的中的用途
CN117186239A (zh) * 2022-01-30 2023-12-08 南京瑞初医药有限公司 融合蛋白及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US5767247A (en) * 1994-11-11 1998-06-16 Noboru Kaneko Anti-annexin-V monoclonal antibodies, and preparation and use thereof
US6284475B1 (en) * 1997-07-11 2001-09-04 Mount Sinai School Of Medicine Of The City Of New York Assays for diagnosis of thrombophilic disease
US5932712A (en) * 1997-07-31 1999-08-03 Incyte Pharmaceuticals, Inc. Annexin binding protein
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
HUP0203160A3 (en) * 1999-11-05 2006-02-28 Warner Lambert Co Prevention of plaque rupture by acat inhibitors
GB0005867D0 (en) * 2000-03-10 2000-05-03 Medinnova Sf Method
EP1267905B1 (de) * 2000-03-10 2005-09-28 Medinnova As Zusammensetzung zur behandlung von herzinsuffizienz
IL135993A0 (en) * 2000-05-05 2001-05-20 Omrix Biopharmaceuticals Pharmaceutical composition for the treatment of fibrosis
EP1278540B1 (de) * 2000-05-05 2008-05-14 Laboratoires Serono SA Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
US6962903B2 (en) * 2001-02-21 2005-11-08 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US20050013778A1 (en) * 2001-04-03 2005-01-20 Theseus Imaging Corporation Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
EP1322957B1 (de) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
US20040042959A1 (en) * 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents

Also Published As

Publication number Publication date
ES2356364T3 (es) 2011-04-07
WO2005099744A1 (en) 2005-10-27
CN1997385B (zh) 2012-01-11
US20080044404A1 (en) 2008-02-21
PL1755642T3 (pl) 2010-06-30
PT1755642E (pt) 2010-04-20
CN1997385A (zh) 2007-07-11
JP2007532617A (ja) 2007-11-15
AU2005232436B2 (en) 2010-03-11
JP2012136536A (ja) 2012-07-19
AU2005232436C1 (en) 2010-08-26
DK1755642T3 (da) 2010-05-10
EP1755642A1 (de) 2007-02-28
AU2005232436A1 (en) 2005-10-27
CA2563408A1 (en) 2005-10-27
CY1109959T1 (el) 2014-09-10
SI1755642T1 (sl) 2010-05-31
CA2563408C (en) 2015-08-25
EP1755642B1 (de) 2010-01-13
DE602005018914D1 (de) 2010-03-04

Similar Documents

Publication Publication Date Title
CY1109959T1 (el) Αννεξινη v για αποτροπη ρηξης αθηροσκληρωτικων πλακων
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
DE60221234D1 (de) Verwendung von füllstoffe als sättigungsmittel
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
TN2012000302A1 (en) Oxyntomodulin peptide analogue
MX2009007644A (es) Compuestos de piperidina heterociclicos sustituidos y usos de los mismos.
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
WO2012143364A3 (en) Cosmetic composition for use in increasing collagen synthesis in skin cells
CR11692A (es) USO DE VARIANTES DE IGF-I PEGiladas PARA EL TRATAMIENTO DE TRASTORNOS NEUROMUSCULARES
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
ATE414531T1 (de) Verbesserte antimikrobielle peroxidase- zusammensetzungen
EA201171084A1 (ru) Гели, образующиеся при сдвиговой деформации, и композиции, содержащие гели, образующиеся при сдвиговой деформации
IL183481A (en) Combinations containing vegf-trap with 5-fluorouracil are useful in the treatment of neoplastic diseases
WO2009140265A3 (en) Methods and compositions for the treatment of obesity
TW200730190A (en) New combination to treat liver fibrosis
TW200640496A (en) Visco-supplement composition and methods
WO2009095646A3 (en) Peptides from factor viii
UY31847A (es) Nuevos derivados de imidazopiridinas, composiciones conteniéndolos y aplicaciones
NZ702645A (en) A method of improving liver function
WO2007139970A3 (en) Men1 gene for diagnosis and treatment of diabetes
ATE553114T1 (de) Verbindungen zur verminderung der aggregation von amyloid-beta-peptid
PT1904048E (pt) Inibidores de glepp-1 no tratamento de distúrbios autoimunes e/ou inflamatórios

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1755642

Country of ref document: EP